Infanrix (Dtpa) (Diphtheria Toxoid, Tetanus Toxoid, Pertussis Toxoid, Pertussis Filamentous Haemagglutinin, Pertussis)

Infanrix is a vaccine that targets bacterial toxins and pertussis antigens to prevent specific infectious diseases.

• Diphtheria: provides active immunity that prevents diphtheria infection.
• Tetanus: induces antibodies that protect against tetanus caused by Clostridium tetani.
• Pertussis: creates immunity that reduces the risk of whooping cough in infants and young children.

• Infanrix contains diphtheria toxoid, tetanus toxoid and acellular pertussis components (pertussis toxin, filamentous haemagglutinin, pertactin). After intramuscular injection, these antigens stimulate the immune system to produce specific antibodies, establishing active immunity that neutralises the diphtheria and tetanus toxins and blocks pertussis bacterial adhesion and toxin activity.

Common Side Effects

• Pain, redness or swelling at the injection site.
• Low‑grade fever within 24‑48 hours.
• Irritability or fussiness in infants.
• Loss of appetite.
• Mild headache.
• Temporary soreness of the arm.

Serious or Rare Side Effects

• Anaphylactic reaction with difficulty breathing.
• Seizures or convulsions.
• Persistent high fever.
• Encephalopathy or neurological symptoms.
• Hypotonic‑hyporesponsive episodes.
• Severe allergic rash or angioedema.

Infanrix should be administered only after evaluating the individual's health status and vaccine history.

• Contraindication: severe allergic reaction to any component of the vaccine.
• Not for infants younger than six weeks of age.
• Delay vaccination if the child has a moderate or severe acute illness.
• Use with caution in immunocompromised patients; response may be reduced.
• Observe the child for at least 15 minutes after injection for signs of serious reaction.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Infanrix may interact with other immunizations or immune‑modulating therapies.

Major Interactions (Avoid)

• Live viral vaccines administered within four weeks before or after Infanrix.
• Immunoglobulin or blood products containing antibodies given within three months.
• High‑dose immune globulin therapy within three months of vaccination.

Moderate Interactions (Monitor Closely)

• Systemic corticosteroids that may blunt antibody response.
• Ongoing immunosuppressive therapy (e.g., chemotherapy, biologics).
• Chronic illnesses that could affect immune competence.
• Concurrent administration of other non‑live vaccines may require spacing.
• Anticonvulsant medications may mask febrile reactions.